宫颈发育不良和癌的生物标志物。
Biomarkers of cervical dysplasia and carcinoma.
机构信息
Department of Pathology, Hospital Level 2, Room 766, Stony Brook University Medical Center, Stony Brook, NY 11794-7025, USA.
出版信息
J Oncol. 2012;2012:507286. doi: 10.1155/2012/507286. Epub 2011 Oct 29.
Abstract
Although cervical cytology screening has decreased the incidence of cervical cancer in industrialized countries, HPV-related cervical disease, including premalignant and malignant lesions, continues to represent a major burden on the health care system. Some of the problems include the potential for either under- or overtreatment of women due to decreased specificity of screening tests as well as significant interobserver variability in the diagnosis of cervical dysplastic lesions. Although not completely elucidated, the HPV-driven molecular mechanisms underlying the development of cervical lesions have provided a number of potential biomarkers for both diagnostic and prognostic use in the clinical management of these women.
摘要
虽然在工业化国家，宫颈细胞学筛查已经降低了宫颈癌的发病率，但 HPV 相关的宫颈疾病，包括癌前病变和恶性病变，仍然对医疗保健系统构成重大负担。一些问题包括由于筛查试验特异性降低，以及在诊断宫颈发育不良病变方面观察者间存在显著差异，导致对女性的治疗可能不足或过度。虽然尚未完全阐明，但 HPV 驱动的宫颈病变发展的分子机制为这些女性的临床管理提供了一些潜在的诊断和预后生物标志物。
相似文献
1
Biomarkers of cervical dysplasia and carcinoma.宫颈发育不良和癌的生物标志物。
J Oncol. 2012;2012:507286. doi: 10.1155/2012/507286. Epub 2011 Oct 29.
2
A review of methods for detect human Papillomavirus infection.人乳头瘤病毒感染检测方法的研究进展。
Virol J. 2012 Nov 6;9:262. doi: 10.1186/1743-422X-9-262.
3
Anal dysplasia screening: an evidence-based analysis.肛门发育异常筛查：基于证据的分析。
Ont Health Technol Assess Ser. 2007;7(4):1-43. Epub 2007 Jun 1.
4
Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.人乳头瘤病毒检测与宫颈发育异常和癌的分子标志物
Cancer. 2007 Feb 25;111(1):1-14. doi: 10.1002/cncr.22425.
8
Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.p16INK4a 细胞学、HPV mRNA 和 HPV DNA 检测在识别异常筛查结果女性中的高级别宫颈上皮内瘤变的性能。
Gynecol Oncol. 2010 Oct;119(1):98-105. doi: 10.1016/j.ygyno.2010.06.011. Epub 2010 Jul 8.
9
Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical.HPV检测在子宫颈癌初筛中的有效性和成本效益评估。
GMS Health Technol Assess. 2007 Sep 4;3:Doc08.
10
[Importance of the Pap smear in the age of HPV testing].[巴氏涂片在人乳头瘤病毒检测时代的重要性]
Ther Umsch. 2021;78(2):93-98. doi: 10.1024/0040-5930/a001243.
引用本文的文献
1
The Immune Response Generated against HPV Infection in Men and Its Implications in the Diagnosis of Cancer.男性针对人乳头瘤病毒（HPV）感染产生的免疫反应及其在癌症诊断中的意义。
Microorganisms. 2023 Jun 18;11(6):1609. doi: 10.3390/microorganisms11061609.
2
Evaluation of HPV E6/E7 mRNA Detection in Clinically Suspected Cases of Cervical Cancer with Abnormal Cytology: Time to Upgrade the Screening Protocols.对细胞学异常的临床疑似宫颈癌病例中HPV E6/E7 mRNA检测的评估：是时候升级筛查方案了。
J Lab Physicians. 2022 Jul 4;14(3):336-342. doi: 10.1055/s-0042-1748919. eCollection 2022 Sep.
3
Human papillomavirus and cervical cancer: an insight highlighting pathogenesis and targeting strategies.人乳头瘤病毒与宫颈癌：对发病机制及靶向治疗策略的深入剖析
Virusdisease. 2022 Jun;33(2):132-154. doi: 10.1007/s13337-022-00768-w. Epub 2022 May 30.
4
Cervical Carcinoma: Oncobiology and Biomarkers.宫颈癌：肿瘤生物学与生物标志物。
Int J Mol Sci. 2021 Nov 22;22(22):12571. doi: 10.3390/ijms222212571.
5
Expression analysis of p16 and TOP2A protein biomarkers in cervical cancer lesions and their correlation with clinico-histopathological characteristics in a referral hospital, Tanzania.在坦桑尼亚的一家转诊医院，分析宫颈癌病变中 p16 和 TOP2A 蛋白生物标志物的表达及其与临床病理特征的相关性。
PLoS One. 2021 Oct 27;16(10):e0259096. doi: 10.1371/journal.pone.0259096. eCollection 2021.
6
Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers.人乳头瘤病毒：一项关于所有与人乳头瘤病毒相关癌症的流行病学、致癌机制、诊断方法及治疗的综述研究
Med J Islam Repub Iran. 2021 May 22;35:65. doi: 10.47176/mjiri.35.65. eCollection 2021.
7
Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo and in vitro.紫杉醇和 miR-34a 联合超声微泡对体内外宫颈癌的协同抗肿瘤作用。
Clin Transl Oncol. 2020 Jan;22(1):60-69. doi: 10.1007/s12094-019-02131-w. Epub 2019 May 15.
8
Risk Categorization with Different Grades of Cervical Pre-Neoplastic Lesions - High Risk HPV Associations and Expression of p53 and RARβ.不同级别宫颈肿瘤前病变的风险分类——高危型人乳头瘤病毒关联以及p53和视黄酸受体β的表达
Asian Pac J Cancer Prev. 2019 Feb 26;20(2):549-555. doi: 10.31557/APJCP.2019.20.2.549.
9
Development and validation of a method for human papillomavirus genotyping based on molecular beacon probes.基于分子信标探针的人乳头瘤病毒基因分型方法的建立与验证。
PLoS One. 2018 Nov 29;13(11):e0207930. doi: 10.1371/journal.pone.0207930. eCollection 2018.
10
Characterization of JAK2 V617F (1849 G > T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections.人乳头瘤病毒和性传播感染相关宫颈癌中JAK2 V617F（1849G>T）突变的特征分析
J Cancer Prev. 2018 Jun;23(2):82-86. doi: 10.15430/JCP.2018.23.2.82. Epub 2018 Jun 30.
本文引用的文献
1
p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study.p16/ki-67 双染细胞学在 ASCUS 和 LSIL 巴氏细胞学筛查中的应用：来自欧洲意义不明确或轻度异常巴氏细胞学研究的结果。
Cancer Cytopathol. 2011 Jun 25;119(3):158-66. doi: 10.1002/cncy.20140. Epub 2011 Mar 25.
2
Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.用 p16/Ki-67 双重染色细胞学对巴氏细胞学阴性、HPV 阳性的宫颈癌筛查结果进行分类。
Gynecol Oncol. 2011 Jun 1;121(3):505-9. doi: 10.1016/j.ygyno.2011.02.033. Epub 2011 Mar 21.
3
Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples.Cervista HPV 16/18 基因分型检测在宫颈细胞学样本中的分析性能。
J Clin Virol. 2011 May;51(1):38-43. doi: 10.1016/j.jcv.2011.01.016. Epub 2011 Mar 4.
4
Using biomarkers as objective standards in the diagnosis of cervical biopsies.在宫颈活检诊断中使用生物标志物作为客观标准。
Am J Surg Pathol. 2010 Aug;34(8):1077-87. doi: 10.1097/PAS.0b013e3181e8b2c4.
5
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
6
The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results.p16INK4a 细胞学与 HPV 检测在 ASC-US 和 LSIL 巴氏细胞学结果分流中检测高级别宫颈疾病的敏感性和特异性。
Am J Clin Pathol. 2010 Jul;134(1):12-21. doi: 10.1309/AJCP3CD9YKYFJDQL.
7
p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia.p16（INK4a）在预测宫颈细胞学中的高级别上皮内瘤变方面优于高危型人乳头瘤病毒检测。
Cancer Cytopathol. 2010 Jun 25;118(3):146-56. doi: 10.1002/cncy.20078.
8
Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.Cervista HPV HR 和 16/18 基因分型检测用于 ASC-US 细胞学女性的临床验证。
Gynecol Oncol. 2010 Aug 1;118(2):116-22. doi: 10.1016/j.ygyno.2010.04.013. Epub 2010 May 21.
9
Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia.联合检测 p16INK4a 可显著提高诊断高级别宫颈上皮内瘤变的准确性。
Am J Clin Pathol. 2010 Mar;133(3):395-406. doi: 10.1309/AJCPXSVCDZ3D5MZM.
10
Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens.宫颈液基细胞学和活检标本中p16INK4a与ProEx C免疫染色的比较
Diagn Cytopathol. 2010 Aug;38(8):564-72. doi: 10.1002/dc.21251.
Zotero 插件